October 30, 2023: GSK plc has announced significant findings from a phase III trial trial for Jemperli (dostarlimab), a potential treatment for advanced or recurrent endometrial cancer. The phase III RUBY trial, combining Jemperli with standard chemotherapy, has delivered positive results.
Improving patient survival
The RUBY trial, a global study, explores the effects of Jemperli in treating endometrial cancer. It’s divided into two parts, examining different combinations of treatments and assessing survival and disease progression. The results show great promise for patients.
The trial achieved its main goal of improving overall patient survival, demonstrating a meaningful benefit. Overall survival, defined as the proportion of trial patients on the drug who were alive compared to those on a placebo, was one of two primary goals in the Phase III trial, GSK said.
The trial’s results are promising for two specific groups: those with mismatch repair deficiency (dMMR) or microsatellite instability-high (MSI-H) and those without these conditions. The company reported that the study met its primary endpoint of progression-free survival and demonstrated a 72% and 36% reduction in the risk of disease progression.
The goal is to help a broader range of patients with endometrial cancer.
The path forward
GSK’s Senior Vice President, Hesham Abdullah, is excited about these results. The next step is to share the detailed findings with regulators and the scientific community. This could potentially revolutionize the way endometrial cancer is treated.
It’s important to note that Jemperli has already received approval for certain patients with endometrial cancer in the United States and the United Kingdom. It’s also under review in other countries, offering hope to patients worldwide.
Endometrial cancer affects the inner lining of the uterus. It’s the most common gynecological cancer in developed countries, with thousands of new cases each year. Jemperli is an antibody that fights endometrial cancer by blocking certain receptors.